Reprofit Brno strengthens its scientific footprint

We are proud to announce that our clinic Reprofit Brno has once again played an active role in advancing scientific knowledge in reproductive medicine. Their team contributed to the study Non-standardized protein background in IVF media linked to serum-derived albumin supplementation, published in the prestigious  Journal of Assisted Reproduction and Genetics (JARG).

The research focused on the variability of protein backgrounds in embryo culture media, which are essential for IVF treatment. It revealed that even media considered standardized may contain unexpected proteins, primarily as a result of using serum-derived human albumin. These proteins vary across production batches and may complicate the analysis of the embryonic secretome – the substances released by embryos during their early development. The study therefore highlights an important challenge for both research and clinical practice: the outcomes  may be influenced not only by the embryos themselves, but also by the composition of the media in which they are cultured.

Our participation in this project reflects FutureLife’s commitment to bridging clinical practice and scientific research, actively contributing to progress in the field of reproductive medicine. We extend our sincere thanks to Zuzana Holubcová and her research team, whose scientific leadership and expertise were the driving force behind this study. We are also grateful to Soňa Kloudová and her team—especially Barbora Maierová—as well as Pavel Otevřel, for their valuable support and contributions throughout the project.

This achievement reinforces FutureLife’s mission to be not only a provider of healthcare, but also a partner in science and innovation. By supporting and engaging in such projects, we continue to strive for ever higher standards of care for our patients.